{"id":55455,"date":"2023-04-03T14:06:53","date_gmt":"2023-04-03T12:06:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/"},"modified":"2023-04-03T14:06:53","modified_gmt":"2023-04-03T12:06:53","slug":"rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/","title":{"rendered":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)"},"content":{"rendered":"
\n

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st<\/sup> Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).\n<\/p>\n

<\/a><\/p>\n

\nAdditional information about the ISTH 2023 Congress is available at: https:\/\/www.isth2023.org\/<\/a>.\n<\/p>\n

\nAbout Rallybio<\/b>\n<\/p>\n

\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 complement inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.\n<\/p>\n

\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut\u2019s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com<\/a> and follow us on LinkedIn<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements that are based on our management\u2019s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the expected progress, results and plans for RLYB212. The forward-looking statements in this press release are only predictions and are based largely on management\u2019s current expectations and projections about future events and financial trends that management believes may affect Rallybio\u2019s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and 1b clinical trials for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio\u2019s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio\u2019s Annual Report on Form 10-K for the period ended December 31, 2022, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor<\/b>
Ami Bavishi
\n
Head of Investor Relations and Communications
\n
475-47-RALLY (Ext. 282)
\n
abavishi@rallybio.com<\/a>\n<\/p>\n

\nHannah Deresiewicz
\n
Stern Investor Relations, Inc.
\n
212-362-1200
\n
hannah.deresiewicz@sternir.com<\/a>\n<\/p>\n

\nMedia<\/b>
Tara DiMilia
\n
908-369-7168
\n
Tara.dimilia@tmstrat.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55455","6":"format-standard","7":"category-industry"},"yoast_head":"\nRallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-03T12:06:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)\",\"datePublished\":\"2023-04-03T12:06:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/\"},\"wordCount\":655,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005560\\\/en\\\/1407047\\\/21\\\/Press_Release_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/\",\"name\":\"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005560\\\/en\\\/1407047\\\/21\\\/Press_Release_Logo.jpg\",\"datePublished\":\"2023-04-03T12:06:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005560\\\/en\\\/1407047\\\/21\\\/Press_Release_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005560\\\/en\\\/1407047\\\/21\\\/Press_Release_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/","og_locale":"en_US","og_type":"article","og_title":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend","og_description":"NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-03T12:06:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)","datePublished":"2023-04-03T12:06:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/"},"wordCount":655,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/","url":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/","name":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg","datePublished":"2023-04-03T12:06:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005560\/en\/1407047\/21\/Press_Release_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rallybio-announces-acceptance-of-abstract-for-rlyb212-at-the-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-isth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55455"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55455\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}